Uncategorized
Medidur meets study endpoint of preventing posterior uveitis recurrence at 6 months
Medidur met its primary efficacy endpoint of preventing the recurrence of posterior uveitis for 6 months in a phase 3 clinical trial, pSivida announced in a press release.Medidur, an injectable micro-insert introduced into the back of the eye, provides a sustained release of 0.18 mg of fluocinolone acetonide at a controlled rate for 3 years. The micro-insert is the same that is used in Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences) for the treatment of diabetic macular edema.